Literature DB >> 18372904

Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon.

Kevin M Haigis1, Krystle R Kendall, Yufang Wang, Ann Cheung, Marcia C Haigis, Jonathan N Glickman, Michiko Niwa-Kawakita, Alejandro Sweet-Cordero, Judith Sebolt-Leopold, Kevin M Shannon, Jeffrey Settleman, Marco Giovannini, Tyler Jacks.   

Abstract

Kras is commonly mutated in colon cancers, but mutations in Nras are rare. We have used genetically engineered mice to determine whether and how these related oncogenes regulate homeostasis and tumorigenesis in the colon. Expression of K-Ras(G12D) in the colonic epithelium stimulated hyperproliferation in a Mek-dependent manner. N-Ras(G12D) did not alter the growth properties of the epithelium, but was able to confer resistance to apoptosis. In the context of an Apc-mutant colonic tumor, activation of K-Ras led to defects in terminal differentiation and expansion of putative stem cells within the tumor epithelium. This K-Ras tumor phenotype was associated with attenuated signaling through the MAPK pathway, and human colon cancer cells expressing mutant K-Ras were hypersensitive to inhibition of Raf, but not Mek. These studies demonstrate clear phenotypic differences between mutant Kras and Nras, and suggest that the oncogenic phenotype of mutant K-Ras might be mediated by noncanonical signaling through Ras effector pathways.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18372904      PMCID: PMC2410301          DOI: 10.1038/ng.115

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  36 in total

1.  BRAF mutation predicts sensitivity to MEK inhibition.

Authors:  David B Solit; Levi A Garraway; Christine A Pratilas; Ayana Sawai; Gad Getz; Andrea Basso; Qing Ye; Jose M Lobo; Yuhong She; Iman Osman; Todd R Golub; Judith Sebolt-Leopold; William R Sellers; Neal Rosen
Journal:  Nature       Date:  2005-11-06       Impact factor: 49.962

2.  Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility.

Authors:  J K Voice; R L Klemke; A Le; J H Jackson
Journal:  J Biol Chem       Date:  1999-06-11       Impact factor: 5.157

3.  PTEN-deficient intestinal stem cells initiate intestinal polyposis.

Authors:  Xi C He; Tong Yin; Justin C Grindley; Qiang Tian; Toshiro Sato; W Andy Tao; Raminarao Dirisina; Kimberly S Porter-Westpfahl; Mark Hembree; Teri Johnson; Leanne M Wiedemann; Terrence A Barrett; Leroy Hood; Hong Wu; Linheng Li
Journal:  Nat Genet       Date:  2007-01-21       Impact factor: 38.330

4.  Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.

Authors:  John Rinehart; Alex A Adjei; Patricia M Lorusso; David Waterhouse; J Randolph Hecht; Ronald B Natale; Oday Hamid; Mary Varterasian; Peggy Asbury; Eric P Kaldjian; Stephen Gulyas; David Y Mitchell; Roman Herrera; Judith S Sebolt-Leopold; Mark B Meyer
Journal:  J Clin Oncol       Date:  2004-10-13       Impact factor: 44.544

5.  Cre-lox-regulated conditional RNA interference from transgenes.

Authors:  Andrea Ventura; Alexander Meissner; Christopher P Dillon; Michael McManus; Phillip A Sharp; Luk Van Parijs; Rudolf Jaenisch; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-06       Impact factor: 11.205

6.  Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.

Authors:  Ultan McDermott; Sreenath V Sharma; Lori Dowell; Patricia Greninger; Clara Montagut; Jennifer Lamb; Heidi Archibald; Raul Raudales; Angela Tam; Diana Lee; S Michael Rothenberg; Jeffrey G Supko; Raffaella Sordella; Lindsey E Ulkus; A John Iafrate; Shyamala Maheswaran; Ching Ni Njauw; Hensin Tsao; Lisa Drew; Jeff H Hanke; Xiao-Jun Ma; Mark G Erlander; Nathanael S Gray; Daniel A Haber; Jeffrey Settleman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-06       Impact factor: 11.205

Review 7.  Increasing complexity of Ras signaling.

Authors:  S L Campbell; R Khosravi-Far; K L Rossman; G J Clark; C J Der
Journal:  Oncogene       Date:  1998-09-17       Impact factor: 9.867

8.  Insulin stimulation of a MEK-dependent but ERK-independent SOS protein kinase.

Authors:  K H Holt; B G Kasson; J E Pessin
Journal:  Mol Cell Biol       Date:  1996-02       Impact factor: 4.272

9.  Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context.

Authors:  Carmen Guerra; Nieves Mijimolle; Alma Dhawahir; Pierre Dubus; Marta Barradas; Manuel Serrano; Victoria Campuzano; Mariano Barbacid
Journal:  Cancer Cell       Date:  2003-08       Impact factor: 31.743

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

View more
  291 in total

Review 1.  Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras.

Authors:  Anica Wandler; Kevin Shannon
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

2.  Annexin A10 is a marker for the serrated pathway of colorectal carcinoma.

Authors:  Sara A Sajanti; Juha P Väyrynen; Päivi Sirniö; Kai Klintrup; Jyrki Mäkelä; Anne Tuomisto; Markus J Mäkinen
Journal:  Virchows Arch       Date:  2014-11-14       Impact factor: 4.064

3.  c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma.

Authors:  Rafael B Blasco; Sarah Francoz; David Santamaría; Marta Cañamero; Pierre Dubus; Jean Charron; Manuela Baccarini; Mariano Barbacid
Journal:  Cancer Cell       Date:  2011-04-21       Impact factor: 31.743

4.  LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma.

Authors:  Wenjin Liu; Kimberly B Monahan; Adam D Pfefferle; Takeshi Shimamura; Jessica Sorrentino; Keefe T Chan; David W Roadcap; David W Ollila; Nancy E Thomas; Diego H Castrillon; C Ryan Miller; Charles M Perou; Kwok-Kin Wong; James E Bear; Norman E Sharpless
Journal:  Cancer Cell       Date:  2012-06-12       Impact factor: 31.743

5.  Genetic and Chemical Models of Colorectal Cancer in Mice.

Authors:  Mandayam O Nandan; Vincent W Yang
Journal:  Curr Colorectal Cancer Rep       Date:  2010-03-10

Review 6.  The intestinal stem cell.

Authors:  Luis A Chia; Calvin J Kuo
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

7.  A role for the epidermal growth factor receptor signaling in development of intestinal serrated polyps in mice and humans.

Authors:  Gerold Bongers; Luciana R Muniz; Michelle E Pacer; Alina C Iuga; Nanthakumar Thirunarayanan; Erik Slinger; Martine J Smit; E Premkumar Reddy; Lloyd Mayer; Glaucia C Furtado; Noam Harpaz; Sergio A Lira
Journal:  Gastroenterology       Date:  2012-05-26       Impact factor: 22.682

8.  Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.

Authors:  Elda Grabocka; Yuliya Pylayeva-Gupta; Mathew J K Jones; Veronica Lubkov; Eyoel Yemanaberhan; Laura Taylor; Hao Hsuan Jeng; Dafna Bar-Sagi
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

9.  Analysis of the tumor-initiating and metastatic capacity of PDX1-positive cells from the adult pancreas.

Authors:  Irene Ischenko; Oleksi Petrenko; Michael J Hayman
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-18       Impact factor: 11.205

10.  IQGAP1 Scaffold-MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal.

Authors:  Christian B Gocke; Ross McMillan; Qiuju Wang; Asma Begum; Vesselin R Penchev; Syed A Ali; Ivan Borrello; Carol Ann Huff; William Matsui
Journal:  Mol Cancer Ther       Date:  2016-08-29       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.